The Centers for Medicare and Medicaid Services on Tuesday morning unveiled the first 10 drugs subject to price negotiations under the Inflation Reduction Act.
The list (in order) includes:
- Bristol Myers Squibb’s Eliquis
- Lilly’s Jardiance
- Johnson & Johnson’s Xarelto
- Merck’s Januvia
- AstraZeneca’s Farxiga
- Novartis’ Entresto
